NCT02414204View on ClinicalTrials.gov

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NACompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2018

Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
DRUG

Sildenafil

Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.

OTHER

Placebo

Placebo will be over encapsulated to identical to drug comparison

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT02414204 - Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula | Biotech Hunter | Biotech Hunter